Sun Life Financial Inc. (SLF) Cash Flow Statement

The extreme quarterly swings in operating cash flow—ranging from negative to over $4 billion—suggest that reported OCF is heavily influenced by non-operating items such as investment portfolio activity and derivative settlements, not just premium and claim flows. The 2026Q1 surge to $4.1B appears tied to large investment purchases and sales, indicating that the 'underwriting cash' line is not a clean measure of float generation. Investors should focus on the longer-term average, which appears modest relative to the company's $1B+ quarterly net income, implying that core underwriting cash conversion is weaker than headline earnings suggest.

The volatility in claims payments—ranging from zero in 2025Q4 to $13.4B in 2024Q3—appears to reflect the timing of large reinsurance transactions and catastrophe-related settlements rather than a steady trend. The 2026Q2 figure of $12.4B is notably high, suggesting possible lumpy payments for group benefits or reinsurance arrangements. This pattern warrants monitoring for whether it indicates a structural increase in claims costs, particularly in the US health segment following the DentaQuest acquisition, or simply quarter-specific timing.

The absence of investment purchase and sale data in most quarters indicates that the company may be classifying these flows elsewhere or that activity is immaterial in those periods. The 2026Q1 net purchase of $2.1B (purchases of $20.4B vs sales of $18.3B) suggests a modest increase in invested assets, possibly reflecting premium inflows or strategic allocation shifts. The 2025Q4 net purchase of $4.3B was larger, indicating a more aggressive deployment into fixed income or alternatives, which could be a response to higher yields. This pattern implies that portfolio cash flows are not a steady source of liquidity but rather episodic, tied to market opportunities and liability matching.

The capital return program appears aggressive relative to operating cash generation, with dividends alone exceeding OCF in 2026Q2. Over the past ten quarters, cumulative dividends and buybacks of approximately $6.5B compare to cumulative OCF of roughly $17B, suggesting that on average the company generates sufficient cash, but quarterly mismatches are common. The 2026Q2 shortfall is notable and may indicate reliance on portfolio liquidation or external financing, though the company's strong balance sheet and access to capital markets likely mitigate this. Investors should monitor whether the dividend growth rate (from $344.7M in 2024Q1 to $563M in 2026Q2) remains sustainable if investment income or underwriting cash flows weaken.

The wide swings in OCF/NI—from -0.38 in 2025Q1 to 7.69 in 2026Q1—indicate that reported net income is not a reliable proxy for cash generation. The 2026Q2 ratio of 0.11 implies that most of the $1.1B net income was not converted to operating cash, possibly due to large claims payments or changes in working capital. This divergence is typical for insurers under IFRS 17, where revenue recognition and reserve movements create timing differences. The persistence of low conversion quarters suggests that investors should rely on underlying earnings and CSM growth rather than OCF to assess cash-generating ability.